key: cord-0847787-kd7thuhg
authors: Zhou, Wen Qing; Chen, Yun; Liu, Di; Yang, Dong Liang; Zheng, Xin
title: Severe liver injury of coronavirus disease 2019 (COVID‐19) in recovery
date: 2020-12-10
journal: J Dig Dis
DOI: 10.1111/1751-2980.12960
sha: cc4b07da7f3128177612e240d2385da580215195
doc_id: 847787
cord_uid: kd7thuhg

nan

). The patient developed shortness of breath on day 10 after his admission and his oxygen saturation (SpO 2 ) was declined to 92% once. He was given oxygen therapy at 6 L/min via nasal cannula from day 10 to day 17 after the initial symptom (fever) onset.

Based on his epidemiologic history, clinical symptoms, typical viral F I G U R E 1 Computed tomography scans of the patient at A, day 12 (25 January 2020), B, day 15 (28 January 2020), C, day 53 (6 March 2020), and D, day 71 (24 March 2020) after the initial symptom onset. Multiple infectious lesions in bilateral lungs were observed in A and B, which were taken during the patient's first admission. While less infectious lesions in bilateral lungs were observed in C and D, which were taken during his second admission pneumonia sign on chest CT, and positive SARS-CoV-2 RNA test, he was diagnosed as having a severe COVID-19.

Enoxacin, compound glycyrrhiza tablets, and Lianhua Qingwen granules were administered for 10 days during the patient's hospitalization. The vital signs of the patient became stable on day 16 after symptom onset. Hence, enoxacin and compound glycyrrhiza tablets were discontinued. Instead, the patient was given traditional Chinese On 4 March 2020 (day 51), the patient presented with fever, nausea, vomiting, loss of appetite, and extreme fatigue ( Figure 2 ). He was readmitted to the hospital with severe abnormalities of liver function, mild renal dysfunction, and significantly increased C-reactive protein (CRP) and procalcitonin (PCT) ( Table 1) , but denied any pre-existing liver diseases. Chest CT scan showed significant improvement when compared to previous CT scans ( Figure 1C the pulmonary lesions were mostly improved. We speculate that severe liver injury in this patient was not caused by a COVID-19

relapse, but might have been caused by sepsis, which was considered based on fever, significantly elevated inflammatory index, multiorgan dysfunction, 3 and rapid recovery after antibiotic treatment, although his blood culture was negative twice. We also noticed that the abso- treatments. We did not use substitution therapy, anticoagulants, anticoagulant factor concentrates, antifibrinolytic treatment, and so on. And DIC was resolved following control of the preliminary disease.

Immune dysfunction was considered in COVID-19 patients evidenced by lymphopenia and higher neutrophil/lymphocyte ratio, decreased CD4 + T and CD8 + T cell counts, and suppressed interferon-γ production by CD4 + T cells. 8 This patient had decreased lymphocyte count and increased NLR. Unfortunately, lymphocyte subset analysis was not performed in this patient. Nevertheless, the patient quickly recovered from severe sepsis following effective treatment. 3 We speculate that severe infection, such as sepsis, can still be resolved by remaining immune response in severe COVID-19 cases.

Overall, our report may be a good supplement to the current understanding of liver injury in COVID-19.

The patient provided written informed consent to publish the current report.

None. 

China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China

Liver injury in COVID-19: management and challenges

The third international consensus definitions for sepsis and septic shock (Sepsis-3)

Drug-induced liver injury

Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation

How I treat disseminated intravascular coagulation

Disseminated intravascular coagulation

Clinical and immunological features of severe and moderate coronavirus disease 2019